NLRP3 Overexpression Associated With Poor Prognosis and Presented as an Effective Therapeutic Target in Osteosarcoma
Authors:
Open Access
- 28 July 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Despite the development of diagnostic and treatment strategies, the survival outcome of patients with osteosarcoma remains poor. Nod-like receptor protein 3 (NLRP3) plays a crucial role in the inflammasome pathway, which is related to the progression of various tumors. However, the effect of NLRP3 on osteosarcoma has not yet been well explored. Our study aimed to investigate the role of NLRP3 in the malignant biological behavior of osteosarcoma as well as its therapeutic value. Immunohistochemistry was applied to investigate the NLRP3 expression in osteosarcoma and osteochondroma specimens. Cell Counting Kit-8, colony formation, wound healing, transwell, and flow cytometry assays were used to explore the contribution of NLRP3 to the proliferation, migration, invasion, apoptosis and cell cycle distribution of osteosarcoma cells in vitro. Western blot was performed to evaluate the expression of NLRP3 and the related proteins in osteosarcoma cell lines after the blockade of NLRP3 using CY-09 and lentivirus intervention. Furthermore, tumor formation assay was used to analyze the effect of NLRP3 on the growth of osteosarcoma in vivo. The results showed that the NLRP3 protein was overexpressed in osteosarcoma, which was independently correlated with the poor prognosis of patients. Moreover, NLRP3 suppression by the inhibitor of CY-09 or lentivirus-induced gene knockdown inhibited the cell proliferation, migration, invasion and promoted the cell apoptosis and G1 cell cycle arrest in osteosarcoma via targeting the inflammasome pathway. Our in vivo results confirmed that the inhibition of NLRP3 suppressed the tumor formation of osteosarcoma. In conclusion, NLRP3 may be regarded as an independent prognostic biomarker and a potential therapeutic target for osteosarcoma.Keywords
Funding Information
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Fujian Medical University
This publication has 34 references indexed in Scilit:
- Creating In Vitro Three-Dimensional Tumor Models: A Guide for the Biofabrication of a Primary Osteosarcoma ModelTissue Engineering Part B: Reviews, 2021
- NLRP3 regulates alveolar bone loss in ligature‐induced periodontitis by promoting osteoclastic differentiationCell Proliferation, 2020
- P2X7 Receptor (P2X7R) of Microglia Mediates Neuroinflammation by Regulating (NOD)-Like Receptor Protein 3 (NLRP3) Inflammasome-Dependent Inflammation After Spinal Cord InjuryMedical Science Monitor, 2020
- Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine modelJournal of Neuroinflammation, 2019
- MicroRNA‐22 suppresses cell proliferation, migration and invasion in oral squamous cell carcinoma by targeting NLRP3Journal of Cellular Physiology, 2018
- Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinomaCellular and Molecular Life Sciences, 2017
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disordersJournal of Experimental Medicine, 2017
- NLRP3 inflammasome activation promotes inflammation-induced carcinogenesis in head and neck squamous cell carcinomaJournal of Experimental & Clinical Cancer Research, 2017
- Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing’s sarcomaMedical Science Monitor, 2011
- Immunity, Inflammation, and CancerCell, 2010